Get started
Author

Marzieh K. Golmakani

Observed names: Marzieh Golmakani, Marzieh K Golmakani
ORCID: 0000-0002-2111-0773
Observed ORCID: 0000-0002-2111-0773
OpenAlex ID: A5037570319
Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer
2017 · Natalie J. Engmann, Marzieh K. Golmakani, et al. · JAMA Oncology · 234
PDF
Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population
2022 · Karla Kerlikowske, Shuai Chen, et al. · JNCI Journal of the National Cancer Institute · 52
PDF
Super Learner for Survival Data Prediction
2020 · Marzieh K. Golmakani, Eric C. Polley · The International Journal of Biostatistics · 35
A first-in-human, phase 1 study of the SHP2 inhibitor PF-07284892 as monotherapy and in combination with different targeted therapies in oncogene-driven, treatment-resistant solid tumors.
2023 · Alexander E. Drilon, Melissa Lynne Johnson, et al. · Journal of Clinical Oncology · 8
Nonhomogeneous Markov chain for estimating the cumulative risk of multiple false positive screening tests
2021 · Marzieh K Golmakani, Rebecca A Hubbard, et al. · Biometrics · 2
Supplementary Table S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Figure 1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Table 3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Results from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Table S2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Table 5 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Table S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Methods from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S3 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Data from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Table S4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Table 2 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S6 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Table 4 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Table 1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
Supplementary Figure S1 from A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al.
A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers
2026 · Marwan Fakih, Toshihiko Doi, et al. · Cancer Research Communications
Works count: 25
Citation count: 331
H-index: 4
I10-index: 3
Year
Topic
Type